ML7 has the potential to bring an effective, targeted therapeutic response in patients who suffer from dry eye syndromes. Preclinical trials of the eye-drop formulation of Neuroptis Biotech's ML7 product have yielded positive results, and are published in Investigative Ophthalmology and Visual Science.

ML7 is the first molecule in a new therapeutic class, and is intended for use in the treatment of eye surface diseases, particularly dry eye.

In this preclinical animal study, ocular surface inflammation induced by benzalkonium was evaluated in rats. Pretreatment with ML7 reduced ophthalmic symptoms and inflammation significantly compared with placebo (P 

"We will start phases 1 and 2 in the next few months, as soon as the European Medicines Agency (EMA) has given its approval for trials on human subjects," said Eric Belot, Neuroptis Biotech CEO. According to the company, human clinical trials of ML7are planned for mid-2014.

Articles

Cataract & Refractive

ML7 has the potential to bring an effective, targeted therapeutic response in patients who suffer from dry eye syndromes. Preclinical trials of the eye-drop formulation of Neuroptis Biotech's ML7 product have yielded positive results, and have recently been published.